| Indien | Türkei | Österreich | |
| Strahlentherapie bei Darmkrebs | von $3,200 | von $7,000 | von $12,000 |
| Stereotaktische Radiochirurgie | von $5,200 | von $4,500 | von $17,000 |
| Pneumonektomie | von $8,800 | von $10,872 | von $50,000 |
| Lungenkrebsoperation | von $5,800 | von $17,000 | von $42,000 |
| Chemotherapie bei Brustkrebs | von $3,500 | von $1,200 | von $15,000 |
Bookimed erhebt keine zusätzlichen Gebühren für Lungenkrebs Stadium 4-Behandlungspreise. Die Preise stammen aus den offiziellen Preislisten der Kliniken. Sie zahlen direkt in der Klinik für Ihre Behandlung bei Ihrer Ankunft im Land.
Bookimed setzt sich für Ihre Sicherheit ein. Wir arbeiten nur mit medizinischen Einrichtungen zusammen, die hohe internationale Standards bei der Behandlung von Lungenkrebs Stadium 4 einhalten und über die notwendigen Lizenzen verfügen, um internationale Patienten weltweit zu behandeln.
Bookimed bietet kostenlose fachliche Unterstützung. Ein persönlicher medizinischer Koordinator unterstützt Sie vor, während und nach Ihrer Behandlung und hilft Ihnen bei allen Fragen. Sie sind auf Ihrer Lungenkrebs Stadium 4-Behandlungsreise nie allein.
Dr. Sridhar ist am HCG Manavata Cancer Centre auf Strahlentherapie spezialisiert, insbesondere bei fortgeschrittenem Lungenkrebs.
Über 30.000 durchgeführte PET-Scans – Dr. Chaitainya Borde ist am HCG Manavata Cancer Centre auf fortschrittliche Nuklearmedizin spezialisiert.
Dr. Shaunak präsentierte seine Forschung zum Magenkarzinom auf dem renommierten Gastrointestinal Cancer Symposium der ASCO. Sein Schwerpunkt liegt auf molekularbasierten zielgerichteten Therapien für Lungenkrebs.
Stage 4 lung cancer is generally considered incurable because it has spread to distant organs. Treatment aims to manage the disease as a chronic condition. Modern therapies focus on prolonging survival, relieving physical symptoms, and maximizing your quality of life through personalized care.
Bookimed Expert Insight: Precision diagnostics in India, such as PET-CT and molecular profiling, are reshaping treatment expectations. For example, Dr. Shruti Kate at HCG Manavata has presented research on how immunotherapy and metronomic therapy can extend life. Clinics like Manipal Goa even use IBM Watson to help oncologists select the most effective drug protocols based on global data. This level of technology helps shift the goal from simple palliation to long-term disease control.
Patient Consensus: Patients note that while a permanent cure is rare, achieving no evidence of disease is possible with the right targeted drugs. They emphasize that molecular profiling is a vital first step before starting any therapy.
Next-Generation Sequencing (NGS) is essential for identifying specific genetic mutations that plan stage 4 lung cancer treatment. This genomic profile allows doctors to select highly effective targeted therapies. It ensures patients avoid aggressive chemotherapy when oral drugs or immunotherapies better match the tumor biology.
Bookimed Expert Insight: Indian oncology centers like HCG Manavata Cancer Centre use NGS to participate in global clinical trials for new mutations. Their specialists, like Dr. Shruti Kate, often wait for molecular results before starting systemic therapy. This approach is vital since advanced centers report that tumor biology dictates the path more than scans alone.
Patient Consensus: Patients note that waiting for NGS results is stressful but necessary to avoid the wrong treatment. They emphasize ensuring the biopsy sample is large enough to prevent the need for a second procedure.
The median life expectancy for stage 4 lung cancer in India ranges from 6 to 12 months. Modern therapies increase 5-year survival rates to 40% for eligible patients. High-volume JCI-accredited centers in Delhi and Mumbai utilize targeted medications to manage advanced cases.
Bookimed Expert Insight: Clinical experience significantly impacts survival. Dr. Raj Nagarkar at HCG Manavata has performed over 50,000 cancer surgeries. Data shows that centers with high patient volumes, like Manipal and Apollo serving 1,000,000+ patients annually, offer more robust access to international clinical trials. This exposure often provides patients access to newer drugs before they become standard care.
Patient Consensus: Patients note that testing for driver mutations is essential. While initial stage 4 diagnoses feel overwhelming, many find that responding well to immunotherapy leads to unexpectedly long stability.
Families manage advanced therapy side effects through rigorous neurological monitoring, environmental safety protocols, and proactive symptom tracking. At JCI-accredited centers like Apollo Hospital Indraprastha, caregivers act as frontline observers for immune reactions. They coordinates logistics nearby clinics to ensure immediate access during critical recovery windows.
Bookimed Expert Insight: Patient volume data reveals a significant expertise gap in India. Manipal Hospitals serves over 2,000,000 patients annually. This high frequency helps clinical teams better train families. Specialized oncologists like Dr. Shruti Kate provide research-backed protocols for managing chronic lung cancer symptoms. Large networks offer better home-care coordination than smaller facilities.
Patient Consensus: Many families treat managing side effects like a full-time logistics project. They recommend keeping a shared phone log for medication times and oxygen readings. Patients often feel targeted therapies are more tolerable than chemotherapy, despite the persistent daily fatigue.